BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

BioMarin Pharmaceutical (NASDAQ: BMRN) will host its third quarter 2026 financial results call and webcast on November 2, 2026.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

BioMarin Pharmaceutical (NASDAQ: BMRN) will host its third quarter 2026 financial results call and webcast on November 2, 2026.

The call begins at 4:30 p.m. ET. President and Chief Executive Officer Alexander Hardy will discuss the results and provide a general business update. A live audio webcast will be available on BioMarin's investor website, with a replay archived for one week following the call.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/26/2026 - 09:00 AM EDT

SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET to discuss third quarter 2026 financial results and provide a general business update.

Dial-in Number
U.S. / Canada Dial-in Number: +1 833-461-5787
International Dial-in Number: +1 626-884-3620
Conference Call ID: 324 588 583

U.S. / Canada Replay Dial-in Number: +1 833-309-1852
International Replay Dial-in Number: +44 800 007 4044
Playback ID: 324 588 583

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.